Evidence map›Paper›PMID 23402849›Full record

ArticleNeuroscience2013

Neuroprotection of rat retinal ganglion cells mediated through alpha7 nicotinic acetylcholine receptors.

K Iwamoto, D Mata, D M Linn, C L Linn

Open access · greenAbstract read
In one paragraph

Article in Neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Involvement ofFrontiers in molecular biosciences · 2020
    Article
  9. Article
  10. Article
  11. Veterinary world · 2016
    Article
  12. Review
  13. Article
  14. Neurodegeneration and Neuroprotection in Glaucoma.The Yale journal of biology and medicine · 2016
    Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

K IwamotoWestern Michigan University, Department of Biological Sciences, Kalamazoo, MI 49008, USA.
D Mata
D M Linn
C L Linn
Western Michigan University · USGrand Valley State University · US

Funding

Prevention of RGC loss in an in vitro excitotoxic model and an in vivo model of gR15EY022795 · NEI · WESTERN MICHIGAN UNIVERSITY · PI LINN, CINDY L · 2012 to 2012
$416k
ACh neuroprotection against excitotoxicity in RGCsR15EY017314 · NEI · WESTERN MICHIGAN UNIVERSITY · PI LINN, CINDY L · 2007 to 2007
$222k
NEI NIH HHS EY017314NEI NIH HHS R15 EY017314NEI NIH HHS R15 EY022795
6 · The paper itself

Abstract

Glutamate-induced excitotoxicity is thought to play an important role in several neurodegenerative diseases in the central nervous system (CNS). In this study, neuroprotection against glutamate-induced excitotoxicity was analyzed using acetylcholine (ACh), nicotine and the α7 specific nicotinic acetylcholine receptor (α7 nAChR) agonist, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride (PNU-282987), in cultured adult rat retinal neurons. Adult Long Evans rat retinas were dissociated and retinal ganglion cells (RGCs) were isolated from all other retinal tissue using a two-step panning technique. Once isolated, RGCs were cultured under various pharmacological conditions to demonstrate excitotoxicity and neuroprotection against excitotoxicity. After 3 days, RGCs were immunostained with antibodies against the glycoprotein, Thy 1.1, counted and cell survival was assessed relative to control untreated conditions. 500 μM glutamate induced excitotoxicity in large and small RGCs in an adult rat dissociated culture. After 3 days in culture with glutamate, the cell survival of large RGCs decreased by an average of 48.16% while the cell survival of small RGCs decreased by an average of 42.03%. Using specific glutamate receptor agonists and antagonists, we provide evidence that the excitotoxic response was mediated through α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainic acid (KA) and N-methyl-d-aspartate (NMDA) glutamate receptors through an apoptotic mechanism. However, the excitotoxic effect of glutamate on all RGCs was eliminated if cells were cultured for an hour with 10 μM ACh, 100 μM nicotine or 100 nM of the α7 nAChR agonist, PNU-282987, before the glutamate insult. Inhibition studies using 10nM methyllycaconitine (MLA) or α-bungarotoxin (α-Bgt) supported the hypothesis that neuroprotection against glutamate-induced excitotoxicity on rat RGCs was mediated through α7 nAChRs. In immunocytochemical studies, double-labeled experiments using antibodies against Thy 1.1 and α7 nAChR subunits demonstrated that both large and small RGCs contained α7 nAChR subunits. The data presented in this study support the hypothesis that ACh and nicotinic acetylcholine receptor (nAChR) agonists provide neuroprotection against glutamate-induced excitotoxicity in adult rat RGCs through activation of α7 nAChR subunits. These studies lay the groundwork required for analyzing the effect of specific α7 nAChR agonists using in vivo models of excitotoxicity. Understanding the type of ACh receptors involved in neuroprotection in the rat retina could ultimately lead to therapeutic treatment for any CNS disease that involves excitotoxicity.

Indexed as

6-Cyano-7-nitroquinoxaline-2,3-dioneAcetylcholinealpha7 Nicotinic Acetylcholine ReceptorAnimalsApoptosisBenzamidesBridged Bicyclo CompoundsCells, CulturedDizocilpine MaleateDose-Response Relationship, DrugDrug InteractionsFemaleGlutamic AcidIn Situ Nick-End LabelingMaleNeuroprotective Agents6-Cyano-7-nitroquinoxaline-2,3-dioneAcetylcholinealpha7 Nicotinic Acetylcholine ReceptorBenzamidesBridged Bicyclo CompoundsChrna7 protein, ratDizocilpine MaleateGlutamic AcidNeuroprotective AgentsNicotineNicotinic AgonistsPNU-282987Receptors, Nicotinic

Identifiers

PMID23402849
PMCPMC3609885
OpenAlexW2043779120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.